Abstract: Nitric oxide (NO) is recognized as a mediator and regulator of inflammatory responses. It possesses cytotoxic properties that are aimed against pathogenic microbes, but it can also have damaging effects on host tissues. NO reacts with soluble guanylate cyclase to form cyclic guanosine monophosphate (cGMP), which mediates many of the effects of NO. NO can also interact with molecular oxygen and superoxide anion to produce reactive nitrogen species that can modify various cellular functions. These indirect effects of NO have a significant role in inflammation, where NO is produced in high amounts by inducible nitric oxide synthase (iNOS) and reactive oxygen species are synthesized by activated inflammatory cells. The present review deals with NO production and signaling in inflammation, especially in relation to human neutrophils and eosinophils.
INTRODUCTION
Since its discovery in 1987 [1, 2] , nitric oxide (NO) has been a target of intensive research and drug development. NO is a gaseous signaling molecule that regulates various physiological and pathophysiological responses in the human body. These include circulation and blood pressure, platelet function, host defense, and neurotransmission in central nervous system and in peripheral nerves.
The role of NO in host defense and immune responses was started to be understood at the second half of the 1980s. Stuehr and Marletta reported that mouse macrophages produce nitrite and nitrate in response to bacterial lipopolysaccharide [3] , and a compound with the reactivity of NO proved to be an intermediate in the process [4] . Hibbs and co-workers were able to identify NO as an effector molecule in macrophagemediated cytotoxicity [5, 6] . Since then, a number of reports on the effects of NO in inflammatory responses have been published. High levels of NO are produced in response to inflammatory stimuli and mediate proinflammatory and destructive effects. However, like most other inflammatory mediators, NO has also protective effects in some inflammatory responses.
The physiological and pathophysiological role of NO in the respiratory system has been reviewed recently [7, 8] . NO acts as a neurotransmitter in NANC nerves and regulates smooth muscle tone. NO is also involved in the host defense in bronchial epithelium, and it acts as an inflammatory mediator in pathological states. Inhaled NO may have clinical implications in certain conditions as a bronchodilator and vasodilator, and NOS inhibitors are believed to be of benefit in inflammatory lung diseases. In addition, exhaled NO can be measured as a marker of asthma and other inflammatory lung diseases. In the present review, we will discuss the regulation of NO production in response to inflammatory stimuli as well as the targets of NO, especially in neutrophilic and eosinophilic inflammation.
BIOSYNTHESIS OF NO
NO is synthesized from L-arginine in a reaction catalyzed by a family of nitric oxide synthase (NOS) enzymes. Active NOS is a tetramer formed by two NOS proteins and two calmodulin molecules. Conversion of Larginine to NO and L-citrulline requires also NADPH and O 2 as cosubstrates and (6R)-tetrahydrobiopterin (BH 4 ), FAD, FMN and iron protoporphyrin IX (haem) as co-factors [9] [10] [11] .
Three different NOS isoforms have been characterized. The neuronal NOS (nNOS, NOS I) is predominantly expressed in neurons in brain and peripheral nervous system [12] . Endothelial NOS (eNOS, NOS III) is mainly expressed in endothelial cells [13] . Both nNOS and eNOS are constitutively expressed and are inactive in resting cells. Increase in free intracellular calcium concentration ([Ca 2+ ] i ) stabilizes the binding of calmodulin to eNOS and nNOS, and activates the enzyme to produce NO. Stimuli that increase the [Ca 2+ ] i (eg. acetylcholine in endothelial cells) trigger the production of NO, and when the [Ca 2+ ] i decreases, the NO production ceases. That regulation makes NO production by constitutively expressed NOSs transient and short lasting [9] [10] [11] .
The third isoform of the NOS family is the inducible NOS (iNOS, NOS II). No iNOS expression is found in most resting cells. Exposure to
*Address correspondence to this author at the Immunopharmacology Research Group, Medical School, FIN-33014 University of Tampere, Finland; Fax: + 358 3 3551 8082; E-mail: eeva.moilanen@uta.fi microbial products, such as lipopolysaccharide (LPS) and dsRNA or proinflammatory cytokines such as interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) induces the expression of iNOS gene in various inflammatory and tissue cells. Binding of calmodulin to iNOS is tight even at low [Ca 2+ ] i , and therefore, iNOS is also called as a calcium-independent NOS, and it can constantly produce high levels of NO for prolonged periods [11, 14, 15] .
REGULATION OF iNOS EXPRESSION
Although iNOS expression has been shown in various mouse and human cells, there are marked cell type and species specific differences in the responsiveness of iNOS expression to different stimuli [14] [15] [16] . For instance, responses in human cells seem to be quite different from those in mouse cells, which have been widely used in the studies on iNOS expression. Many mouse cells readily express iNOS in response to LPS or to a single cytokine, whereas human cells usually require a combination of different cytokines for detectable iNOS expression and NO synthesis. Furthermore, iNOS is expressed at high levels in activated murine macrophages, but it has been difficult to induce iNOS in human monocytes / macrophages in vitro, although iNOS expression in macrophages in inflamed human tissues has been shown in ex vivo studies [17] [18] [19] .
Regulation of Murine iNOS Transcription
Transcription of mouse iNOS gene is regulated by ~1 kb promoter [20, 21] , which contains putative binding sites for a number of transcription factors. In vivo footprinting assay revealed LPS-induced binding to octamer (Oct), E-box, nuclear factor kappa B (NF-κB) and interferonstimulated response element (ISRE) sites [22] .
The mouse iNOS promoter contains two NF-κB elements, which are critical for iNOS expression as site directed mutagenesis of either of these sites significantly reduces promoter activity, and chemical inhibitors of NF-κB prevent iNOS expression and NO production [23] [24] [25] [26] .
IFN-γ is an efficient enhancer of iNOS expression in most cells. iNOS expression is seriously impaired in macrophages from mice deficient of signal transducer and activator of transcription 1 (Stat1) [27] , IFN regulatory factor-1 (IRF-1) [28] or IFN consensus sequence binding protein (ICSBP) [29] , demonstrating the importance of IFN-responsive transcription factors in iNOS expression. iNOS promoter contains a functional GAS site which binds Stat1 [30] , and an ISRE site which binds a complex of IRF-1 and ICSBP [31, 32] .
Next to a proximal NF-κB site is an Oct site, which is also required for iNOS promoter activity. Oct site binds members of the POU family of transcription factors (Oct-1, Brn-3a, Brn-3b) and high mobility group proteins (HMG-I(Y)) [33] [34] [35] [36] [37] . HMG-I(Y) alone cannot promote transcription, but it augments and stabilizes the p50/p65 binding to NF-κB site [35] . Additional transcription factors which have been shown to regulate mouse iNOS promoter activity include Epithelium-specific Ets (ESE-1) [38] and CAAT/enhancer binding protein beta (C/EBPβ) [39] . The role of activator protein 1 (AP-1) family of transcription factors in the regulation of murine iNOS transcription is unclear. Existence of both positive and negative regulatory AP-1 sites has been reported [40, 41] , but the composition of AP-1 which binds to these sites is not known. Overexpression of c-fos, fosB and c-jun suppresses iNOS promoter activity [41] . Stat3 [42] , Elk-3 [43] and upstream stimulatory factors 1 and 2 (USF-1 and USF-2) [44] have been shown to negatively regulate iNOS transcription.
Regulation of Human iNOS Transcription
The promoter of the human iNOS gene is rather different from the murine iNOS promoter. Deletion analysis of the human iNOS 5'flanking region indicates presence of regulatory elements on the length of 16 kb [45] . There is conflicting evidence about the presence of regulatory elements on the first 4.7 kb of the human promoter. In some studies, induction by cytokines was reported when promoter constructs containing the first 3.2 kb [46] and 1 kb [47] were used. However, other reports observed only basal activity but no induction by cytokines with constructs containing first 1 -4.7 kb of the promoter [45, [48] [49] [50] [51] .
Human iNOS promoter is activated by NF-κB. A proximal NF-κB site seems to be important in controlling transcription of human iNOS [50, 52, 53] , although lack of functionality for this site has also been reported [51] . Several other functional NF-κB sites have been found further upstream of the promoter [53, 54] .
IFN-γ is an important cytokine for iNOS expression in human cells like in murine cells (see above). However, the IFN-γ -inducible factors that regulate the activity of human iNOS promoter are less well-characterized than those that regulate the mouse promoter. Two functional GAS sites have been found. The upstream site contains overlapping NF-κB and Stat1 binding sites, and binding of both of these factors to this site is required for promoter activity [55] .
Additional factors shown to regulate human iNOS transcription include C/EPBβ [56] and Krüppel-like factor 6 (KLF6) [57] . Both positive and negative regulatory AP-1 sites have been found in the human iNOS promoter [58] [59] [60] , and the activity of the human promoter is suppressed by overexpressing c-jun and c-fos [61] . Human iNOS promoter contains also a negative regulatory element, which binds NF-κB repressing factor, that is a constitutively expressed silencer that acts as a suppressor of basal transcription [62] .
The inter-species differences in the promoters mostly explain the differences in the inducibility of iNOS expression between human and murine cells [48] . However, activation of NF-κB and Stat1 pathways seems to be important for both human and mouse iNOS transcription.
Post-Transcriptional Regulation of iNOS Expression
Recent evidence supports the idea that regulation of iNOS mRNA stability is an important means to regulate iNOS expression. In unstimulated cells, nuclear run-on assays show continuous iNOS transcription, and human iNOS promoter constructs have basal activity. However, no iNOS mRNA or protein can be detected in these cells, suggesting that the iNOS mRNA is highly unstable in unstimulated cells [45, 49, 63] . The basal activity of the human iNOS promoter is suppressed, and its inducibility is increased if the luciferase construct also contains the 3'-untranslated region (UTR) of the human iNOS mRNA [64] . Both human and murine 3'-UTRs contain AU-rich elements (AREs) [65, 66] , which are characterized by the presence of AUUUA pentamers or UUAUUUAUU nonamers. AREs have been shown to control mRNA stability and translation of many transiently expressed cytokines and growth factors [67] .
There is only fragmentary data on factors / mechanisms that regulate iNOS mRNA stability. Treatment with inhibitor of translation, cycloheximide, stabilizes mouse iNOS mRNA, suggesting that stability of iNOS mRNA is regulated by factors, which require de novo protein synthesis, or that the stability is coupled to translation [68] [69] [70] . It seems that the 3'-UTR ARE sequences of human iNOS mRNA alone are not sufficient for destabilization, but additional elements in the 3'-UTR are required [71] . 3'-UTR of iNOS mRNA binds an mRNA stability regulating protein HuR [71] . Down-regulation of HuR expression results in reduced iNOS expression and NO production without reduction in promoter activity. This suggests that HuR stabilizes iNOS mRNA [71] . Protein kinase C δ (PKC δ) [72] and c-Jun N-terminal kinase (JNK) [73] have been implicated in the regulation of iNOS mRNA stability. Reduced iNOS mRNA stability has also been observed after treatment with transforming growth factor-β (TGF-β) [74] , dexamethasone [75] , 8-bromo-cyclic guanosine monophosphate (cGMP) [76] and intracellular calcium elevating agents [77] . Increased iNOS mRNA stability has been observed after treatment with forskolin (activates adenylate cyclase) or dibutyryl cyclic adenosine monophosphate (cAMP) (membrane permeable cAMP analog) [78, 79] , following BH 4 [80] or the β-adrenergic agonist, isoproterenol [81] .
Interestingly, it was recently shown that in addition to serving as a substrate of NO biosynthesis, L-arginine also controls iNOS expression. The intracellular L-arginine concentration required for maximal NO production is higher than the K m of L-arginine for iNOS. Reduction of intracellular L-arginine concentrations by overexpression of arginase or depletion of extracellular L-arginine reduces iNOS mRNA translation due to inactivation of eukaryotic initiation factor2α, an important factor in initiation of translation [82, 83] .
Signaling Pathways Regulating iNOS Expression
Various signal transduction pathways have been suggested to regulate iNOS expression. The importance of pathways leading to the activation of transcription factors NF-κB and Stat1 have been discussed above. cAMP activating compounds can both enhance [78, [84] [85] [86] and inhibit [86, 87] cytokine induced iNOS expression. Use of PKC activating phorbol esters or PKC inhibitors have mainly suggested a positive role for PKC in cytokine induced iNOS expression [88] [89] [90] , but also a negative role has been reported [91, 92] . This may reflect the observations that different PKC isoforms may have opposite effects [88, 89, 93] . [97] .
The role of the mitogen-activated protein kinases in the regulation of iNOS expression has been investigated intensively. Extracellular signalregulated kinase 1 and 2 have been shown to up-regulate [98] [99] [100] [101] or to have no role [102, 103] in iNOS expression. Also p38 MAP kinase has been reported to up-regulate [101, 104, 105] , down-regulate, [106] [107] [108] or to have no role [109, 110] in iNOS expression. Activation of JNK upregulates iNOS expression [73, 111, 112] .
NO: MOLECULAR MECHANISMS OF ACTION
NO is a reactive molecule that has a variety of effects depending on the relative concentrations of NO and the surrounding milieu in which NO is produced. There are both direct effects of NO that are mediated by the NO molecule itself, and indirect effects of NO that are mediated by reactive nitrogen species produced by the interaction of NO with superoxide anion or with oxygen. cGMP that is produced by the interaction of NO with soluble guanylate cyclase, mediates many of the physiological effects of NO, and it is also an important example of the direct effects of NO.
The molecular mechanisms that mediate the biological activities of NO can be divided into three categories. Firstly, NO reacts readily with transition metals, such as iron, copper and zinc. These metals are abundantly present in prosthetic groups of enzymes and other proteins, and by that mechanism, NO regulates the activity of various enzymes. Secondly, NO is able to induce the formation of S-nitrosothiols from cysteine residues in a reaction called S-nitrosylation. Nitrosylation has been shown to modify the activity of several proteins involved in cellular regulatory mechanisms [113] . Thirdly, NO reacts very quickly with superoxide anion (O 2 -), resulting in the formation of peroxynitrite (ONOO -). Peroxynitrite is a nitrating agent and a powerful oxidant that is able to modify proteins, lipids and nucleic acids.
The first mechanism represents direct effects of NO and the two latter mechanisms are referred as indirect effects of NO. At low concentrations of NO (< 1uM), the direct effects of NO predominate, whereas at higher concentrations (> 1uM), the indirect effects become more important [114] (Fig. 1) .
NO Signaling through Transition Metals
Due to its chemical structure, NO can act as an electron donor in chemical reactions, and thereby is prone to react with transition metals resulting in the formation of metal-nitrosyl complexes. In biological systems, important transition metals that react with NO are iron, copper and zinc.
One of the main targets in NO signaling is soluble guanylate cyclase (sGC). sGC is an enzyme containing a heme structure with ferrous iron, and it converts GTP to an important intracellular signaling molecule cGMP. The basal activity of sGC is low, but it is rapidly activated by even low concentrations of NO (10-100nM) . NO binds directly to the heme in sGS to form a ferrous-nitrosyl-heme complex resulting in changes in the porphyrin ring structure. This leads to the activation of sGC and 400-500-fold increase in the rate of cGMP synthesis [114, 115] . Inflammatory signals, such as bacterial products or proinflammatory cytokines, induce the expression of iNOS that is able to synthesize NO independently of changes in [Ca 2+ ] i . Effects of NO are mediated mainly via three routes. Firstly, NO can react directly with transition metals (e.g. iron, copper and zinc) found in catalytic sites in enzymes like guanylate cyclase. This leads to formation of metal-nitrosyl complexes, and it may result in changes in the catalytic activity of the target enzyme. Secondly, NO can react with cysteinyl residues of proteins forming nitrosothiols in a reaction called S-nitrosylation. S-nitrosylation may alter the activity of proteins in a similar manner as phosphorylation, and it is a reversible event. Thirdly, a reaction between NO and superoxide anion results in a formation of peroxynitrite (ONOO -) that is a strong oxidant and nitrating agent that is able to modify proteins, lipids and nucleic acids.
The principal mediator of cGMP signals is cGMP dependent protein kinase (PKG). PKG is a serine/threonine kinase that is activated upon binding of cGMP. Two types of PKG have been characterized. PKG I is a cytosolic enzyme that is ubiquitously expressed with particularly high expression levels in cerebellum, platelets and smooth muscle cells. PKG I has various targets which are related to smooth muscle relaxation and to platelet and neutrophil activation. [116, 117] . PKG I deficient mice show vascular, intestinal and erectile dysfunction [118, 119] , which stresses the mediator role of cGMP and PKG I in the NO-induced smooth muscle relaxation. PKG II is a membrane-bound protein that is expressed in various tissues but not in the cardiovascular system. It is related to intestinal secretory functions, and PKG II knockout resulted in intestinal secretory defects and dwarfism [120] .
Other factors that convey cGMP mediated signaling are cyclic nucleotide gated channels (CNG), cAMP dependent protein kinase (PKA) and phosphodiesterases. CNGs are voltage gated cation channels that are involved in the processing of visual information in retina [121, 122] . Because the cyclic nucleotide binding domains of PKG and PKA have significant homology, cGMP is able to activate PKA, although with a 50-fold lower selectivity than cAMP [116, 117] . Fourth target of cGMP is phosphodiesterases (PDEs), which catalyze the conversion / inactivation of cAMP or cGMP to 5'AMP and 5'GMP, respectively. Different families of PDEs are either regulated (stimulated or inhibited) by cGMP or they target cGMP. PDE 5 is specific for cGMP, and selective inhibitors of this enzyme are widely used in the treatment of erectile dysfunction. PDE 5 inhibitors, such as sildenafil, enhance cGMP levels and by that mechanism, augment NO-induced vasodilatation in penile vessels [116, 117, 123] .
Another well-documented target of direct NO regulated signaling is cytochrome c oxidase (CcO). CcO is the terminal enzyme of the electron transport chain, which is responsible for the synthesis of ATP in mitochondria. CcO contains two heme moieties and two Cu 2+ centers. NO has been found to inhibit CcO function in a reversible manner, thereby hindering mitochondrial respiration [124, 125] . Another example is catalase, which is a ferric heme containing protein responsible for the metabolism of hydrogen peroxidase. NO reacts with the ferric moiety resulting in the inhibition of catalase function. This leads to the increased intracellular concentrations of hydrogen peroxide, and may contribute to the cytotoxicity of NO [126] .
NO Signaling through S-Nitrosylation
S-nitrosylation of proteins has been recognized as an important mechanism that regulates the functions of the target proteins, and it has been even compared to protein phosphorylation [113] . In aqueous solutions, NO reacts readily with molecular oxygen (O 2 ) forming dinitrogen trioxide (N 2 O 3 ) in a process called as NO autoxidation. N 2 O 3 is decomposed rapidly to nitrosonium ion (NO + ) and nitrite. Nitrosonium ion is responsible for the nitrosylation of thiols, secondary amines and phenolics. Rate of autoxidation is mainly dependent on the concentrations of NO and oxygen, and it is dramatically accelerated within lipid membranes. This means that the rate of formation of N 2 O 3 is high at the site of NO synthesis. This stresses the importance of the distance between the site of NO synthesis and target molecules and subcellular environment and conditions in NO signaling [113] .
Although nitrosylation of proteins is a chemical reaction, there seems to be specificity, which is a requirement for a proper signaling mechanism. For example, p21 ras , a kinase involved in the MAP kinase cascade activation, is a target for NO-based signaling. p21 ras contains four cysteine residues, but only cysteine 118 is nitrosylated resulting in the activation [127] . Another example is coxsackievirus protease A2 that is inhibited by nitrosylation of cysteine 110 [128] . The group of cellular target proteins that are regulated by S-nitrosylation is increasing, and includes transcription factors, kinases involved in signaling cascades, caspases, ion channels and metabolic protein as shown in Table 1 .
NO Signaling through Peroxynitrite
Reaction between NO and superoxide anion (O 2 -) forms ONOO -that is a reactive molecule able to nitrate and oxidize proteins, lipid, and nucleotides. The reaction between NO and superoxide anion is very rapid, the rate constant of the reaction being about three times grater than the rate of superoxide decomposition by superoxide dismutase (SOD). The rate of ONOO -production is strongly dependent on the presence of NO and superoxide, and ONOO -formation is favored in an environment containing equivalent amounts of NO and superoxide. Sources of superoxide production are mainly considered to be mitochondria and immune cells (macrophages and granulocytes), and the synthesis of both NO and superoxide is increased in inflammation [114] .
Excessive peroxynitrite formation leads to nitrated proteins, inhibition of mitochondrial respiration, depletion of cellular energetics, DNA damage, apoptosis and necrotic cell death, resulting in cellular/tissue injury [114, 129] (See Table 2 ). Nitrotyrosine has been used as a marker of peroxynitrite formation and tissue injury. Tyrosine nitration is becoming increasingly recognized also as a functionally significant protein modification. Nitration of proteins and enzymes modulates catalytic activity, cell signaling and cytoskeletal organization. [129] [130] [131] . It is of interest that also the activity of iNOS is regulated by ONOO --mediated nitration. Nitration of iNOS decreases catalytic activity, and this may be a regulatory mechanism in patients with sepsis [132] . NO can also nitrate tyrosine residues within proteins without formation of ONOO -. For example, NO has been shown to nitrate tyrosine residues and thereby 
Ion channels
Ryanodine receptors S-nitrosylation of Cys3635 desensitization [234] NMDA receptor S-nitrosylation of Cys399 inhibition [235] 
Metabolic proteins
Creatine kinase inhibition [236] Ornithine kinase inhibition [237] Lipids peroxidation [242] Mitochondrial enzymes inhibition-depletion in cellular energetics [243] Nitration Prostaglandin I 2 synthase inhibition, reduction in PGI 2 dependent vasorelaxation [244, 245] Manganese SOD inhibition, transplant rejection [246] Cyclooxygenase 1 inhibition [133] Cyclooxygenase 2 inhibition [134] Ribonucleotide reductase inhibition [247] inhibit activity of enzymes cyclooxygenase-1 [133] and cyclooxygenase-2 [134] .
NO AND REGULATION OF IMMUNE RESPONSE
The research that led to the discovery of NO as a signaling factor in biological systems was conducted largely in the field of cardiovascular research. Still, the connection between NO and immune system was observed already in the early days of NO research, when NO was found to be the mediator of macrophage cytotoxicity [6] . Since then, the conception of the role of NO in immune system has broaden vastly. NO has been found to be involved in a number of regulatory functions in inflammation. These include infection control, regulation of signaling cascades and transcription factors, regulation of vascular responses, and regulation of leukocyte rolling, migration, cytokine production, proliferation and apoptosis [14, [135] [136] [137] . Inhibitors of NO synthesis, especially selective iNOS inhibitors have been shown to be antiinflammatory in various forms of experimentally induced inflammation, such as arthritis and colitis [135, [137] [138] [139] , and selective iNOS inhibitors are under development for treatment of inflammatory diseases.
NO AND INFECTION CONTROL
Exposure of inflammatory and tissue cells to bacterial products such as LPS, lipoteichoic acid (LTA), peptidoglycan, or bacterial DNA, or to intact bacteria, induces iNOS expression and enhanced NO production. In these conditions, NO produced by iNOS, partly through formation of peroxynitrite, is a cytotoxic molecule serving as a killing mechanism against invading microbes [140] [141] [142] [143] [144] . The importance of iNOS expression and NO formation in the control of infectious agents is well-established in rodents. To date, data gathered from studies with iNOS gene-deficient mice strongly suggest that NO has a central role in fighting viral, bacterial and protozoa infections in mice [14, 144] .
The role of iNOS expression in antimicrobial reactions in humans is not as clear, and may be less important than in rodents. There is nonetheless evidence that iNOS expression also participates in antimicrobial defense in humans. Increased iNOS expression has been observed in patients with urinary tract infection, tuberculosis, malaria and sepsis [141, [145] [146] [147] , and human neutrophils are found to produce NOderived oxidants through myeloperoxidase [148] . In addition, human macrophages are found to induce iNOS expression and NO formation also in aseptic inflammation, e.g. in rheumatoid arthritis and aseptic loosening of joint implants [18, 19] . In these conditions, the cytotoxic effects of NO that were originally aimed against invading microbes are focused against host tissues and involved in the pathogenesis of inflammation and tissue destruction.
REGULATION OF INFLAMMATORY TRANSCRIPTION FACTORS BY NO
Cellular responses to oxidative and nitrosative stress are often regulated at the level of transcription [149] . Both prokaryotic and eukaryotic cells have transcription factors that are regulated by NO.
NF-κ κ κ κB Pathway
The family of NF-κB/Rel transcription factors has a central role in the regulation of inflammatory responses in mammalian cells including T and B cell proliferation, expression of cytokines and adhesion molecules, as well as regulation of apoptosis. NF-κB activation is involved in several pathological states in humans, such as asthma, rheumatoid arthritis, and inflammatory bowel disease [150] . Activation of NF-κB is essential for iNOS expression (see above), and NO regulates NF-κB at various points in its activation cascade. NO has been shown to inhibit the activity of NF-κB by S-nitrosylation of p50 subunit [151, 152] . In addition, NO has been found to positively modulate NF-κB activation by affecting signaling cascades regulating NF-κB activation. One target is p21 ras , which is activated by oxidative stress and leads to an increase in NF-κB activity. p21 ras is activated by NO through S-nitrosylation of cysteine 118 residue [127, 153, 154] . Dissociation of IκB from NF-κB leads to activation of NF-κB, and it is regulated by enzyme IKK. Transcription and degradation of IKK has been reported to be modulated by NO resulting in reduced activation of NF-κB [155, 156] , whereas low concentrations of NO seem to have an opposite effect [157] . In vivo studies show that NO up-regulates NF-κB activation in situations like hemorrhagic shock and reperfusioninjury [158, 159] .
AP-1 Pathway
AP-1 is a heterodimeric transcription factor consisting of c-fos and cjun subunits. NO regulates AP-1 activity in biological systems but the effects seem to be cell type specific and concentration dependent. NO has been reported to up-regulate the expression of c-fos by a cGMP -dependent mechanism [160, 161] . NO was also found to enhance AP-1 dependent gene expression through activation of JNK [159] . In addition, inhibition of AP-1 dependent transcription by S-nitrosylation of c-fos and c-jun subunits has been reported [162, 163] .
Jak-STAT Pathway
The members of Janus family of tyrosine kinases (Jak1, Jak2, Jak3, Tyk2) are expressed ubiquitously, and are involved in the regulation of a number of cellular functions. They convey extracellular signals from cellular surface to Stat proteins, which in turn activate transcriptional responses within the cell, leading to adaptation to altered extracellular environment [164, 165] . NO has been found to inhibit Jak2 and Jak3 activities in kinase assays [166] . Accordingly, NO produced by activated alveolar macrophages and myeloid suppressor cells inhibited T-cell proliferation, and it was due to NO-dependent inhibition of Jak1 and Jak3 [167, 168] . However, iNOS derived NO was found to enhance Stat3 dependent expression of IL-6 and G-CSF in mice suffering from hemorrhagic shock [158] .
Bacterial Transcription Factors
OxyR is a bacterial transcriptional activator in E.coli that has been shown to be activated by NO through S-nitrosylation of cysteine residues [169, 170] . Another bacterial activator of transcription, SoxR is activated by NO through nitrosylation of [2Fe-2S] clusters within the protein [171] . The activation of these transcription factors leads to protective response to nitrosative and oxidative conditions in bacteria. In yeast, activity of a metal-responsive transcription factor Ace1 was found to be attenuated by NO, possibly through formation of S-nitrosothiols or disulfides [172] .
NO AND NEUTROPHILS
There are interspecies differences in the synthesis of NO by neutrophils. Rodent neutrophils are known to produce NO through iNOS pathway in response to inflammatory stimuli, such as LPS, TNF-α and IFN-γ [173, 174] . Inflammatory stimuli known to induce iNOS in rat neutrophils do not have the same action in human neutrophils, at least under in vitro conditions, and enzymatic production of NO in human neutrophils remains controversial. However, expression of iNOS is likely to occur in certain situations in vivo, because neutrophils isolated from the oral cavity or from urine from patients with urinary track infections were reported to express iNOS [146, 175] . In addition, it was shown that bacterial infection or treatment with cytokines resulted in iNOS expression and nitration of ingested bacteria in human neutrophils [146, 176] . In contrast, many researchers have not found NO synthesis in human neutrophils [177] [178] [179] [180] [181] . We found that even though activated neutrophils did not produce NO, they converted N-hydroxy-L-arginine to nitrite, nitrate and citrulline [181] . Interestingly, enzyme myeloperoxide, which is present in neutrophils, has been shown to produce nitrating oxidants and nitrotyrosine from hydrogen peroxide and nitrite [182] .
In addition to direct antimicrobial effects, NO also regulates neutrophil functions. In in vitro studies, NO / NO-donors have been shown to inhibit degranulation, leukotriene production, superoxide anion generation and chemotactic movement in activated neutrophils [183, 184] . NO has also shown to regulate leukocyte recruitment into the inflammatory focus. Endogenous NO as well as NO-releasing compounds attenuate leukocyte rolling and adhesion to activated endothelium [185] [186] [187] . The underlying mechanism is not known, but it has been related to antioxidant mechanisms of NO [188] and may be dependent on cGMP [187] . NO is also shown to down regulate adhesion molecules that mediate the interaction between leukocytes and endothelium, examples being Pselectin [189] , E-selectin [190] and intracellular adhesion molecule-1 (ICAM-1) [185, 191] .
The role of NO on leukocyte recruitment in vivo is controversial. Mice deficient in eNOS and nNOS were found to have enhanced leukocyte migration in thioglycollate-induced peritonitis, while iNOS deficient mice showed neutrophil infiltration comparable to that seen in wild type mice [189] . iNOS knockout mice have been reported to have markedly increased neutrophil activity and showed exacerbated inflammation and tissue injury in experimental colitis [192, 193] . In contrast, selective inhibition of iNOS has been reported to reduce neutrophil infiltration and tissue injury in trinitrobenzene sulfonic acid -induced colitis [194, 195] . In addition to colitis, NO has been found to regulate leukocyte accumulation in pathological states, such as allergic lung inflammation [196, 197] , septic lung injury [198] and myocardial infarction [159] .
NO AND EOSINOPHILS
The human bronchial epithelial lining expresses iNOS and produces NO [199] , and endogenous NO can be detected in exhaled air [200, 201] . The role of continuous NO production in lung epithelial cells is not clear, but it may be involved in maintaining mucosal defense mechanisms in lungs. Patients with asthma show markedly elevated levels of NO in exhaled air [200, 202, 203] , and they have enhanced iNOS expression and nitrated protein residues in airway epithelium and inflammatory cells [17] . Exhaled NO levels correlate to clinical symptoms of asthma, to sputum eosinophilia, and to markers of eosinophil activation [203, 208] .
NO production in human eosinophils is controversial. Arock et al., reported that eosinophils produce NO when activated by IgEimmunocomplexes through CD23 receptors [209] . Purified eosinophils and human eosinophilic leukemia cell line EOL-3 were found to produce NO and to express iNOS that was highly identical to macrophage iNOS [210] . However, there are also reports suggesting that eosinophils do not express iNOS [211, 212] . Eosinophils may produce reactive nitrogen species also by a NOS-independent manner through eosinophil peroxidase activity [213, 214] .
NO seems to regulate eosinophil accumulation into the site of allergic inflammation by its effects on adhesion molecules, migration and apoptosis. NO and NO donors have been reported to inhibit eosinophil adhesion and migration in vitro [215] [216] [217] . However, in animal models of allergic airway inflammation, iNOS derived NO was associated with accumulation of eosinophils and exacerbation of lung inflammation. Accordingly, iNOS deficient mice showed decreased eosinophil accumulation in experimentally induced allergic lung inflammation. This was associated with increased production of Th1 cytokine, IFNγ, and depletion of IFNγ led to enhanced eosinophil accumulation in lung tissue and more severe inflammation [218, 219] . Interestingly, iNOS knockout mice were more susceptible to pulmonary fibrosis than wild-type mice [220] . This may, however, be rather due to altered neutrophil than eosinophil functions or survival [221, 222] . Interestingly, a recent report showed that NO-releasing budesonide was more potent than budesonide in the inhibition of LPS-induced airway hyperreactivity and leukocyte activation in a guinea-pig model of lung inflammation [223] .
Apoptosis is an important mechanism of clearing eosinophils from the sites of allergic inflammation, and it has been reported to be defective in asthma [224, 225] . Endogenous iNOS derived NO was reported to prevent apoptosis in human eosinophils by mechanisms involving reduced Fas activation [226] and increased Bcl-2 expression [227] . In our recent study, we found that NO was able to reverse IL-5 mediated eosinophil survival [212] . This may reflect the importance of compartmentalization of NO production in NO signaling, and divergent effects of endogenously produced and exogenously given NO.
CONCLUSION
The role of NO in inflammation is not yet completely understood, and several questions remain to be answered. There are reports on iNOS derived NO synthesis in human neutrophils and eosinophils but the findings are still controversial, and the mechanisms that regulate iNOS expression and NO production in granulocytes are mostly unknown. The formation of NO-derived reactive nitrogen species is increased in inflammation in the presence of activated phagocytic cells, and that makes the spectrum of biological effects of NO more complex. NO, like many other inflammatory mediators, seems to have both pro-and anti-inflammatory effects depending on the mechanisms studied, on the concentration of NO and reactive oxygen species, and on the physiological environment. Based on animal experiments so far, selective inhibitors of iNOS have a promise as anti-inflammatory agents in several inflammatory situations, while NOreleasing compounds may suppress granulocyte-mediated cytotoxicity in certain situations like ischemia-reperfusion injury. 
